M. A. Ali, Chronic myeloid leukemia in the era of tyrosine kinase inhibitors: an evolving paradigm of molecularly targeted therapy. Molecular Diagnosis & Therapy, 20 (2016) 315–333.
 J. M. Diamond, J.V. Melo, Mechanisms of resistance to BCR-ABL kinase inhibitors. Leukemia & Lymphoma, 52 (2011) 12–22.
 T. Lahaye, B. Riehm, U. Berger, P. Paschka, M.C. Müller, S. Kreil, K. Merx, U. Schwindel, C. Schoch, R. Hehlmann, A. Hochhaus, Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer, 103 (2005) 1659–1669.
 P. W. Manley, P. Drueckes, G. Fendrich, P. Furet, J. Liebetanz, G. Martiny-Baron, Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics, 1804 (2010) 445-453.
 E. Weisberg, P. Manley, J. Mestan, S. Cowan-Jacob, A. Ray, J. D. Griffin. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. British Journal of Cancer, 94 (2006) 1765-1769.
 J. Y. Blay, M. von Mehren, Nilotinib: A novel, selective tyrosine kinase inhibitor. Seminars in Oncology, 38 (2011) S3-S9.
 A. R. He, A. S. Goldenberg, Treating hepatocellular carcinoma progression following first-line sorafenib: therapeutic options and clinical observations. Therapeutic Advances in Gastroenterology, 6 (2013) 447-458.
 C. H. Takimoto, A. Awada, Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials. Cancer Chemotherapy and Pharmacology, 61 (2008) 535-548.
 S. M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, H. Rong, C. Chen, S. Zhang, P. Vincent, M. McHugh, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research, 64 (2004) e70997109.
 J. W. Panka, D. J. Wang, W. Atkins, M. B. Mier, The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase independent apoptosis in melanoma cells. Cancer Research, 66 (2006) 1611–1619.
 R. Ivaturi, T. M. Sastry, S. Satyaveni, Development and validation of a stability indicating HPLC method for the determination of nilotinib hydrochloride in bulk and pharmaceutical dosage form. International Journal of Pharmacy and Pharmaceutical Sciences, 8 (2016) 41-48.
 A. Barla, K. Buralla, Development and validation of method for the determination of nilotinib by RP-HPLC in bulk and pharmaceutical dosage forms. International Journal of Pharmaceutical Investigation, 3 (2013) 364-367.
 Q. Z. Rafeeque, P. S. Dabhade, Development and method validation of RP-HPLC method for simultaneous estimation and forced degradation of sorafenib tosylate in bulk and pharmaceutical dosage form. Innovational Journal of Chemistry, 1 (2016) 63-71.
 A. Barla, K. K. Buralla, Development and validation of RP-HPLC method for the estimation of nilotinib in bulk and pharmaceutical dosage form, International Journal of Pharmaceutical Investigation, 10 (2020) 364-367.
 A. Rade, K. Patil, T. Thorat, P. Patil and D. Shinde, RP-HPLC method development and validation for the estimation of nilotinib in bulk and tablet dosage form, World Journal of Pharmaceutical Research, 8 (2019) 1286-1294.
 W. Talaat, M. M.Y. Kaddah, Validated analytical method for the determination of sorafenib in dosage form and human plasma in presence of it degradation products, International Journal of PharmTech Research, 12 (2019) 08-21.
 H. A. Alhazmi, D. Allah Moraya, E. Alahdal, M. Kariri, M. A. Bratty, Z. Rehman, S. A. Javed, Ultrafast monolithic HPLC method for simultaneous quantification of the anticancer agents, imatinib and sorafenib: Application to tablet dosage forms, Tropical Journal of Pharmaceutical Research, 17 (2018) 1127-1134.
 I. Khan, Z. Iqbal, A. Khan, M. Hassan, F. Nasir, A. Raza, L. Ahmad, A. Khan, M. A. Mughal, A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib and paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study, Journal of Chromatography B, 1033-1034 (2016) 261-270.
 I. Baranowska, B. Kowalski, Using HPLC method with DAD detection for the simultaneous determination of 15 drugs in surface water and wastewater. Polish Journal of Environmental Studies, 20 (2011) 21-28.
 ICH Guidelines Q2 (R1), Validation of analytical procedures: Text and methodology, Geneva, 2005.